Want to stay in touch with the latest updates from Drug Development and Delivery? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Drug Development & Delivery - The Latest Methods in Drug Development
Is this your feed? Claim it!
Abbott and Novo are expanding their collaboration in diabetes care through a new agreement to commercialize Plosbrio® (semaglutide) across Singapore and additional Asia Pacific markets. The partnership is intended to broaden regional access to semaglutide-based treatment for adults with type 2 diabetes as the prevalence of the disease continues to rise.
Under the agree...
MediPharm Labs has secured a positive regulatory opinion from BSI Group, The Netherlands B.V., marking a key step toward bringing its proprietary metered-dose cannabis inhaler platform to the United Kingdom and selected European markets.
The Toronto-based pharmaceutical company specializing in cannabinoid products received a positive Notified Body Opinion under Article...
Thermo Fisher Scientific has expanded its molecular biology portfolio with the launch of the Invitrogen™ iGlow™ Gel Documentation System, a compact imaging platform designed to streamline routine analysis of protein and nucleic acid gels.
The one-touch system combines DNA, RNA and protein gel imaging capabilities in a single instrument, giving researchers a way to eval...
Swiss specialty pharmaceutical company Dipharma SA has acquired UK-based LogixX Pharma Limited, establishing a direct commercial foothold in the United Kingdom and creating a platform for future product launches targeting rare and chronic diseases.
The acquisition brings together two companies with an established working relationship and a shared focus on developing an...
UK biotechnology company T-Therapeutics has raised $133 million in an oversubscribed Series B financing to advance two investigational T cell receptor (TCR)-based therapies toward clinical proof-of-concept in cancer and autoimmune diseases.
The financing was co-led by Advent Life Sciences and British Business Bank, with participation from new investors Johnson & Jo...